m-Clodrosome is a multilamellar liposome suspension in which clodronate is encapsulated in the aqueous compartments of the mannosylated liposomes. m-Encapsome is formulated and prepared identically to m-Clodrosome except that clodronate is not added to the liposomes. The liposomes are filtered through 2 μm polycarbonate membranes to ensure that larger particles, which may be toxic to animals, are removed from the suspension. Both are prepared and packaged under sterile conditions. When animals or cells are treated with m-Clodrosome, phagocytic cells recognize the liposomes as invading foreign particles and proceed to remove the liposomes from the local tissue or serum via phagocytosis. The liposomes then release clodronate into the cytosol resulting in cell death. Non-encapsulated clodronate cannot cross the cell membrane to initiate cell death. m-Encapsome- control liposomes- are recognized and phagocytosed by the same mechanism as m-Clodrosome. Since the control liposomes do not contain clodronate, the phagocytic cells are not killed. However, phagocytes do respond to the ingestion of control liposomes by cytokine secretion, temporary suspension of phagocytic activity and other responses described in the literature. Mannose receptor targeting by mannosylated liposomes has been demonstrated for a variety of mannosylated lipid conjugates in a variety of liposome morphologies and compositions in several different in vitro and in vivo models. A very large number of publications is about using a hydrophobic derivative of mannose (4-aminophenyl alpha-D-mannopyranoside) rather than using a mannosylated lipid in clodronate liposomes. This is mainly due to the high cost and complexity of synthesizing and conjugating mannose to lipid. 4-aminophenyl alpha-D-mannopyranoside is commercially available and far less expensive than synthesizing mannose conjugated lipid. Why mannose Mannose is one of the carbohydrate components of many bacterial and viral cell surfaces, therefore the ever-efficient, highly redundant immune system has evolved multiple mechanisms for identifying pathogens based on mannose recognition. The animal and plant kingdoms likewise utilize carbohydrate recognition signaling mechanisms including mannose residues. Many publications evaluate other carbohydrates as targeting mechanisms for various cell types, however mannose targeting to phagocytes appears to be one of the more specific mechanisms identified to date. Mammalian cell surface identification molecules based on mannose binding, such as the ICAM family of leukocyte adhesion molecules, target the SIGN family of mannose receptors to accomplish self-recognition in vivo. A well-known and cited study by Umezawa & Eto [1] demonstrates that liposomes containing aminophenyl mannoside were most efficiently incorporated into the mouse brain across the blood brain barrier. The radiolabeled liposomes bearing aminophenyl-alpha-D-mannopyranoside were maximally incorporated into the mouse brain after 48 hours, whereas in the spleen and liver, these radioactivities were maximum after 12 hours. The studies also showed that liposomes were most incorporated was glial cells rather than neuronal cell. The subcellular fractionation study indicates that mannose labeled liposomes are incorporated into lysosomes rich fraction both in liver and brain. Mannosylated macrophage depletion kit is composed of one vial of m-Clodrosome and one vial of m-Encapsome. As an example, a 5-ml kit is composed of 5 ml m-Clodrosome and 9 ml m-Encapsome. Mannosylated fluorescent liposomes (m-Fluoroliposome) suitable for macrophage targeting and tracking are available containing five different fluorescent dyes (DiI, DiO, DiD, DiA and DiR) that covers the entire spectrum. Fluorescent liposomes come in standard and mannosylated form. For more information see here. Clodrosome and Encapsome are standard and non-mannosylated reagents that are used for targenting macrophages in organs and tissues other than central nervous systems.